BioNexus Gene Lab Corp
BGLC
Last
$1.28
Day
+0.8%
1y
-76.2%
5y
-69.5%
52w
-78.8%
SPY YTD
+13.3%
XLB
+6.8%
Earnings
2026-11-1334d
EMA 21
1.35
EMA 50
1.48
EMA 200
2.25
20d high
-20.4%
5y high
-98.7%
5y range
1th
Positions held
Your positionsBGLC isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-27
Hold
avoid
Signal
Strong Sell
Target
$1.44
Stop
$1.09
Stop distance
14.8%
Target vs last
+12.5%
Fundamentals
| Market cap | $3.66M | Enterprise value | $466,414 | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 0.39 | Beta | 2.20 | Dividend yield | 0.00% |
| Revenue growth | -96.6% | Earnings growth | — | Gross margin | 12.3% | Operating margin | -4.0% |
| Profit margin | -82.4% | ROE | -33.7% | ROA | -19.0% | Debt / equity | 0.04 |
| Current ratio | 6.08 | Free cash flow | $68,315 | Analyst recommendation | none | Mean target | — |
| 52w high | $5.89 | 52w low | $1.07 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | $0.0M | $0.5M | $2.5M | $2.3M | — |
| Op margin | -409.7% | -2501.7% | -213.3% | -31.9% | -31.0% | — |
| Net income | -$0.3M | -$0.5M | -$1.0M | -$0.7M | -$0.6M | — |
| Gross margin | 17.0% | -3.5% | -0.8% | 14.8% | 16.3% | — |
| Gross profit | $0.0M | -$0.0M | -$0.0M | $0.4M | $0.4M | — |
| Operating income | -$0.3M | -$0.6M | -$1.0M | -$0.8M | -$0.7M | — |
- Revenue +233% vs prior quarter ($0.1M vs $0.0M).
- Gross margin 17% (was -3.5% prior quarter).
- Operating margin expanded to -409.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | — |
| Op margin | -42.5% | -20.6% | -31.5% | -2.7% | — |
| Net income | -$3.0M | -$1.6M | -$2.6M | -$0.4M | — |
| Gross margin | 14.6% | 13.6% | 13.6% | 11.5% | — |
| Gross profit | $1.1M | $1.3M | $1.3M | $1.3M | — |
| Operating income | -$3.2M | -$2.0M | -$3.1M | -$0.3M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
2026-10-05 · RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
2026-07-28 · BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
Price (daily)
Full chart · RSI · MACD · patternsBGLC · daily-16.7% over 14 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin